WO2003062830A3 - Fibronectin variants and screening methods - Google Patents

Fibronectin variants and screening methods Download PDF

Info

Publication number
WO2003062830A3
WO2003062830A3 PCT/GB2003/000212 GB0300212W WO03062830A3 WO 2003062830 A3 WO2003062830 A3 WO 2003062830A3 GB 0300212 W GB0300212 W GB 0300212W WO 03062830 A3 WO03062830 A3 WO 03062830A3
Authority
WO
WIPO (PCT)
Prior art keywords
fibronectin
screening methods
fibronectin variants
fertility status
patient
Prior art date
Application number
PCT/GB2003/000212
Other languages
French (fr)
Other versions
WO2003062830A2 (en
Inventor
Helen Mardon
David Barlow
Ian Sargent
De Walle Christopher Van
Original Assignee
Isis Innovation
Helen Mardon
David Barlow
Ian Sargent
De Walle Christopher Van
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isis Innovation, Helen Mardon, David Barlow, Ian Sargent, De Walle Christopher Van filed Critical Isis Innovation
Priority to AU2003201688A priority Critical patent/AU2003201688A1/en
Publication of WO2003062830A2 publication Critical patent/WO2003062830A2/en
Publication of WO2003062830A3 publication Critical patent/WO2003062830A3/en
Priority to US10/895,590 priority patent/US20050118661A1/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Urology & Nephrology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A method is provided for assessing fertility status in female patient which comprises determining the level of fibronectin isoform EDIIIA+ and/or EDIIIB+ in an isolated endometrial sample within the implantation window time for the patient and correlating the appearance of said fibronectin isoform with fertility status. Fibronectin variants useful as contraceptive agents are also described.
PCT/GB2003/000212 2002-01-21 2003-01-21 Fibronectin variants and screening methods WO2003062830A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2003201688A AU2003201688A1 (en) 2002-01-21 2003-01-21 Fibronectin variants and screening methods
US10/895,590 US20050118661A1 (en) 2002-01-21 2004-07-21 Fibronectin variants and screening methods

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0201273.0A GB0201273D0 (en) 2002-01-21 2002-01-21 Fibronectin variants and screening methods
GB0201273.0 2002-01-21

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/895,590 Continuation US20050118661A1 (en) 2002-01-21 2004-07-21 Fibronectin variants and screening methods

Publications (2)

Publication Number Publication Date
WO2003062830A2 WO2003062830A2 (en) 2003-07-31
WO2003062830A3 true WO2003062830A3 (en) 2004-03-04

Family

ID=9929422

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2003/000212 WO2003062830A2 (en) 2002-01-21 2003-01-21 Fibronectin variants and screening methods

Country Status (3)

Country Link
AU (1) AU2003201688A1 (en)
GB (1) GB0201273D0 (en)
WO (1) WO2003062830A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2727936B1 (en) 2006-11-22 2016-09-07 Bristol-Myers Squibb Company Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including IGF-IR
FR2976587B1 (en) * 2011-06-20 2015-04-03 Basf Beauty Care Solutions F IN VITRO DOSING METHOD BY IMMUNOLOGICAL TECHNIQUE

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0207751A1 (en) * 1985-06-28 1987-01-07 Delta Biotechnology Limited Fibronectins
WO1992010199A1 (en) * 1990-12-04 1992-06-25 Mount Sinai School Of Medicine Of The City University Of New York Therapeutic and diagnostic applications of fetal fibronectin

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0207751A1 (en) * 1985-06-28 1987-01-07 Delta Biotechnology Limited Fibronectins
WO1992010199A1 (en) * 1990-12-04 1992-06-25 Mount Sinai School Of Medicine Of The City University Of New York Therapeutic and diagnostic applications of fetal fibronectin

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ALTROFF HARRI ET AL: "Synergistic activity of the ninth and tenth FIII domains of human fibronectin depends upon structural stability.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 278, no. 1, 3 January 2003 (2003-01-03), pages 491 - 497, XP002250689, ISSN: 0021-9258 *
FATTORUSSO R ET AL: "NMR structure of the human oncofoetal fibronectin ED-B domain, a specific marker for angiogenesis", STRUCTURE, CURRENT BIOLOGY LTD., PHILADELPHIA, PA, US, vol. 7, no. 4, 15 April 1999 (1999-04-15), pages 381 - 390, XP002124783, ISSN: 0969-2126 *
HUNG T T ET AL: "FIBRONECTIN IN REPRODUCTION", STEROIDS: STRUCTURE, FUNCTION, AND REGULATION, ELSEVIER SCIENCE PUBLISHERS, NEW YORK, NY, US, vol. 54, no. 6, 1 December 1989 (1989-12-01), pages 575 - 582, XP002039706, ISSN: 0039-128X *
MARDON H J ET AL: "Fibronectin splice variants are differentially incorporated into the extracellular matrix of tumorigenic and non-tumorigenic hybrids between normal fibroblasts and sarcoma cells.", JOURNAL OF CELL SCIENCE. ENGLAND MAR 1993, vol. 104 ( Pt 3), March 1993 (1993-03-01), pages 783 - 792, XP002250687, ISSN: 0021-9533 *
VAN DER WALLE CHRISTOPHER F ET AL: "Novel mutant human fibronectin FIII9-10 domain pair with increased conformational stability and biological activity.", PROTEIN ENGINEERING, vol. 15, no. 12, 20 December 2002 (2002-12-20), pages 1021 - 1024, XP002250688, ISSN: 0269-2139 *

Also Published As

Publication number Publication date
GB0201273D0 (en) 2002-03-06
AU2003201688A1 (en) 2003-09-02
WO2003062830A2 (en) 2003-07-31

Similar Documents

Publication Publication Date Title
AU5212199A (en) Methods and kits for diagnosing and determination of the predisposition of diseases
AU2003268912A1 (en) Methods and kits for assays of analytes of interest in tears
AU2001282748A1 (en) Method and kit for determining human geographic or population origin
WO2003091394A3 (en) Methods and kits for detecting a target cell
AU2003241553A1 (en) Method of determining uncertainty associated with noise reduction
AU2003214604A1 (en) Peripheral blood cell markers useful for diagnosing multiple sclerosis and methods and kits utilizing same
AU2003297304A1 (en) Method and means for early detection of pregnancy in animals by combination testing
GB0200425D0 (en) Methods and compositions fo assaying analytes
AU2003300324A1 (en) Novel crystal forms of olanzapine, methods for their preparation and method for the preparation of known olanzapine crystal forms
AU2003260792A1 (en) Method and apparatus for determining the viability of eggs
WO2003062830A3 (en) Fibronectin variants and screening methods
AU2003267898A1 (en) Method and kit for quantitative and qualitative determination of human papillomavirus
AU2003299766A1 (en) Skin testing kit for diagnosing atopy
AU2003217688A1 (en) Method and system for graphical evaluation of iddq measurements
AU2003212405A1 (en) Method for determining the scale of an observation area
AU2003240558A1 (en) Biological results evaluation method
AU2003251775A1 (en) Kits and methods for assessing cardiovascular health
AU2003303347A1 (en) Method and means for determining specific conditions or changes in the uterine epithelium and in the epithelium of other organs
WO2004038412A3 (en) Method for detecting halitosis
AU2003288929A1 (en) Methods and kits for detecting proteins
AU2002251326A1 (en) Method to analyse the kit genotype of pigs
AU2003298141A1 (en) Level measuring system and method
AU2001272909A1 (en) Assessing levels of o6-alkylguanine-dna alkyltransferase in vivo
AU2002367869A1 (en) Methods and kits for testing mutagenicity
AU3986800A (en) Method and kit for indicating the level of bad breath

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 10895590

Country of ref document: US

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP